trial · primary record
Atezolizumab
Fallopian Tube High Grade Serous Adenocarcinoma
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 444 |
| Primary completion | 2027-05-11 |
| Primary endpoint | Incidence of Dose Limiting Toxicities (DLT) of Experimental Regimens |
| Registry ID | NCT02839707 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:45.886Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02839707
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.